Huang Y, Li Y, Pan H, Han L. Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. J Glob Health. 2023;13:04160. https://doi.org/10.7189/jogh.13.04160. (Epub 20231129).

Article  PubMed  PubMed Central  Google Scholar 

Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):e551–67. https://doi.org/10.1016/s2468-2667(20)30190-0.

Article  PubMed  Google Scholar 

Malpetti M, Joie R, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63(6):830–2. https://doi.org/10.2967/jnumed.121.263694.

Article  PubMed  PubMed Central  Google Scholar 

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481–503. https://doi.org/10.1038/s41380-021-01249-0. (Epub 20210830).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R. A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence. J Alzheimers Dis. 2019;70(s1):S165–86. https://doi.org/10.3233/jad-190181.

Article  PubMed  PubMed Central  Google Scholar 

Cole CS, Dafoe A, Tietbohl CK, Jordan SR, Huebschmann AG, Lum HD, et al. Care challenges of home health patients living with dementia: a pathway forward with palliative care. BMC Palliat Care. 2023;22(1):122. https://doi.org/10.1186/s12904-023-01247-9. (Epub 20230829).

Article  PubMed  PubMed Central  Google Scholar 

Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, et al. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022;8(1):170. https://doi.org/10.1038/s41531-022-00410-y. (Epub 20221215).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–81. https://doi.org/10.1038/s41582-019-0244-7. (Epub 20190909).

Article  PubMed  Google Scholar 

Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7(4):278–94. https://doi.org/10.1038/nrn1886.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yiannopoulou KG, Papageorgiou SG. Current and future treatments in alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397. https://doi.org/10.1177/1179573520907397. (Epub 20200229).

Article  PubMed  PubMed Central  Google Scholar 

Kieburtz K, Katz R, McGarry A, Olanow CW. A new approach to the development of disease-modifying therapies for PD; fighting another pandemic. Mov Disord. 2021;36(1):59–63. https://doi.org/10.1002/mds.28310. (Epub 20201007).

Article  PubMed  Google Scholar 

Santiago JA, Karthikeyan M, Lackey M, Villavicencio D, Potashkin JA. Diabetes: a tipping point in neurodegenerative diseases. Trends Mol Med. 2023;29(12):1029–44. https://doi.org/10.1016/j.molmed.2023.09.005. (Epub 20231010).

Article  PubMed  CAS  Google Scholar 

de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101–13. https://doi.org/10.1177/193229680800200619.

Article  PubMed  PubMed Central  Google Scholar 

de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs. 2017;77(1):47–65. https://doi.org/10.1007/s40265-016-0674-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Femminella GD, Livingston NR, Raza S, van der Doef T, Frangou E, Love S, et al. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects? Alzheimers Res Ther. 2021;13(1):47. https://doi.org/10.1186/s13195-021-00784-w. (Epub 20210217).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Patel VN, Chorawala MR, Shah MB, Shah KC, Dave BP, Shah MP, et al. Emerging pathophysiological mechanisms linking diabetes mellitus and Alzheimer’s disease: an old wine in a new bottle. J Alzheimers Dis Rep. 2022;6(1):349–57. https://doi.org/10.3233/adr-220021. (Epub 20220622).

Article  PubMed  PubMed Central  Google Scholar 

Vargas-Soria M, Ramos-Rodriguez JJ, Del Marco A, Hierro-Bujalance C, Carranza-Naval MJ, Calvo-Rodriguez M, et al. Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer’s disease and type two diabetes. Fluids Barriers CNS. 2022;19(1):88. https://doi.org/10.1186/s12987-022-00380-6. (Epub 20221107).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hong CT, Chen KY, Wang W, Chiu JY, Wu D, Chao TY, et al. Insulin resistance promotes Parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. 2020;9(3):740. https://doi.org/10.3390/cells9030740. (Epub 20200317).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yu H, Sun T, He X, Wang Z, Zhao K, An J, et al. Association between Parkinson’s disease and diabetes mellitus: from epidemiology, pathophysiology and prevention to treatment. Aging Dis. 2022;13(6):1591–605. https://doi.org/10.14336/ad.2022.0325. (Epub 20221201).

Article  PubMed  PubMed Central  Google Scholar 

Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson’s disease—a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18(1):83. https://doi.org/10.1186/s13024-023-00676-7. (Epub 20231111).

Article  PubMed  PubMed Central  Google Scholar 

Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–73. https://doi.org/10.1038/s41577-022-00684-6. (Epub 20220304).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lv YQ, Yuan L, Sun Y, Dou HW, Su JH, Hou ZP, et al. Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. Transl Neurodegener. 2022;11(1):14. https://doi.org/10.1186/s40035-022-00288-z. (Epub 20220307).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang Y, Zhang Y, Shi X, Han J, Lin B, Peng W, et al. Metformin and the risk of neurodegenerative diseases in patients with diabetes: a meta-analysis of population-based cohort studies. Diabet Med. 2022;39(6): e14821. https://doi.org/10.1111/dme.14821. (Epub 20220308).

Article  PubMed  CAS  Google Scholar 

Cao G, Gong T, Du Y, Wang Y, Ge T, Liu J. Mechanism of metformin regulation in central nervous system: progression and future perspectives. Biomed Pharmacother. 2022;156: 113686. https://doi.org/10.1016/j.biopha.2022.113686. (Epub 20221013).

Article  PubMed  CAS  Google Scholar 

Zhang QQ, Li WS, Liu Z, Zhang HL, Ba YG, Zhang RX. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: a meta-analysis and systematic review. Medicine. 2020;99(10): e19378. https://doi.org/10.1097/md.0000000000019378.

Article  PubMed  PubMed Central  Google Scholar 

Wahlqvist ML, Lee M-S, Hsu C-C, Chuang S-Y, Lee J-T, Tsai H-N. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18(6):753–8. https://doi.org/10.1016/j.parkreldis.2012.03.010.

Article  PubMed  Google Scholar 

Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized